抗CD20モノクローナル抗体(mAB)の世界市場2024~2028

■ 英語タイトル:Global Anti-CD20 Monoclonal Antibodies (mABs) Market 2024-2028

調査会社Technavio社が発行したリサーチレポート(データ管理コード:IRTNTR73017-23)■ 発行会社/調査会社:Technavio
■ 商品コード:IRTNTR73017-23
■ 発行日:2023年10月16日
■ 調査対象地域:北米、ヨーロッパ、アジア、その他地域
■ 産業分野:医療
■ ページ数:約120
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール(受注後24時間以内)
■ 販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥380,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥608,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[抗CD20モノクローナル抗体(mAB)の世界市場2024~2028]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

抗CD20モノクローナル抗体(mAB)の世界市場 2024〜2028年抗CD20モノクローナル抗体(mAB)市場は、2023-2028年の間に1億1,425.15万米ドル成長し、予測期間中のCAGRは10.31%で加速すると予測されています。当レポートでは、抗CD20モノクローナル抗体(mAB)市場について、市場規模や予測、動向、成長促進要因、課題などの全体的な分析に加え、約25のベンダーを網羅したベンダー分析も掲載しています。
当レポートでは、現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。市場は、併用療法の増加、抗CD20 mABの高い標的親和性と特異性、強力なパイプラインと最近の承認によって牽引されています。

Technavio社の抗CD20モノクローナル抗体(mAB)市場は以下のように区分されます。
製品別
- がん領域
- がん領域
- 免疫学

タイプ別
- 第一世代抗CD20モノクローナル抗体
- 第二世代抗CD20モノクローナル抗体
- 第三世代抗CD20モノクローナル抗体

地域別
- 北米
- 欧州
- アジア
- その他の地域(ROW)

本調査では、今後数年間の抗CD20モノクローナル抗体(mAB)市場の成長を牽引する主な要因の一つとして、治療領域に対する意識の高まりを挙げています。また、償還制度や患者支援プログラムの存在、cd20二重特異性抗体の開発は、市場の大きな需要につながるでしょう。

この調査レポートは、抗CD20モノクローナル抗体(mAB)市場を調査・分析した結果をまとめたものです。
- 抗CD20モノクローナル抗体(mAB)市場規模
- 抗CD20モノクローナル抗体(mAB)市場予測
- 抗CD20モノクローナル抗体(mAB)市場産業分析

本レポートでは、Acrotech Biopharma Inc.、Amgen Inc.、AstraZeneca Plc、Celltrion Healthcare Co. Ltd.、F. Hoffmann La Roche Ltd.、Fosun International Ltd.、Genmab AS、IGM Biosciences Inc.、JSC BIOCAD、LFB SA、Novartis AG、Pfizer Inc.、Regeneron Pharmaceuticals Inc.、Spectrum Pharmaceuticals Inc.、TG Therapeutics Inc.、United BioPharma Inc.、ZHEJIANG HISUN PHARMACEUTICAL Co. Ltd.が含まれています。また、抗CD20モノクローナル抗体(mAB)市場の分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。この調査レポートは、抗CD20モノクローナル抗体(mAB)市場を分析し、市場成長に影響を与える今後の動向や課題についての情報を掲載しています。

本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。当レポートでは、主要ベンダーの分析に加え、包括的な市場とベンダーの状況を掲載しています。
利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、総括することで、市場の詳細な姿を示しています。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示しています。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

1 エグゼクティブサマリー
2 市場状況
3 市場規模
4 過去の市場規模
5 ファイブフォース分析
6 抗CD20モノクローナル抗体(mAB)の世界市場:製品別市場分析
7 抗CD20モノクローナル抗体(mAB)の世界市場:タイプ別市場分析
8 顧客状況
9 地域別状況
10 推進要因・課題・動向
11 企業状況
12 企業分析
13 付録

世界の市場調査レポート販売サイト(H&Iグローバルリサーチ株式会社運営)
*** レポート目次(コンテンツ)***

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market by Geography
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2023
o 3.4 Market outlook: Forecast for 2023-2028
o Exhibit 14: Chart on Global – Market size and forecast 2023-2028 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2023-2028 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
• 4 Historic Market Size
o 4.1 Global anti-CD20 monoclonal antibodies (mABs) market 2018 – 2022
o Exhibit 18: Historic Market Size – Data Table on global anti-cd20 monoclonal antibodies (mabs) market 2018 – 2022 ($ million)
o 4.2 Product Segment Analysis 2018 – 2022
o Exhibit 19: Historic Market Size – Product Segment 2018 – 2022 ($ million)
o 4.3 Type Segment Analysis 2018 – 2022
o Exhibit 20: Historic Market Size – Type Segment 2018 – 2022 ($ million)
o 4.4 Geography Segment Analysis 2018 – 2022
o Exhibit 21: Historic Market Size – Geography Segment 2018 – 2022 ($ million)
o 4.5 Country Segment Analysis 2018 – 2022
o Exhibit 22: Historic Market Size – Country Segment 2018 – 2022 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2023 and 2028
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2023 and 2028
• 6 Market Segmentation by Product
o 6.1 Market segments
o Exhibit 30: Chart on Product – Market share 2023-2028 (%)
o Exhibit 31: Data Table on Product – Market share 2023-2028 (%)
o 6.2 Comparison by Product
o Exhibit 32: Chart on Comparison by Product
o Exhibit 33: Data Table on Comparison by Product
o 6.3 Oncology – Market size and forecast 2023-2028
o Exhibit 34: Chart on Oncology – Market size and forecast 2023-2028 ($ million)
o Exhibit 35: Data Table on Oncology – Market size and forecast 2023-2028 ($ million)
o Exhibit 36: Chart on Oncology – Year-over-year growth 2023-2028 (%)
o Exhibit 37: Data Table on Oncology – Year-over-year growth 2023-2028 (%)
o 6.4 Neurology – Market size and forecast 2023-2028
o Exhibit 38: Chart on Neurology – Market size and forecast 2023-2028 ($ million)
o Exhibit 39: Data Table on Neurology – Market size and forecast 2023-2028 ($ million)
o Exhibit 40: Chart on Neurology – Year-over-year growth 2023-2028 (%)
o Exhibit 41: Data Table on Neurology – Year-over-year growth 2023-2028 (%)
o 6.5 Immunology – Market size and forecast 2023-2028
o Exhibit 42: Chart on Immunology – Market size and forecast 2023-2028 ($ million)
o Exhibit 43: Data Table on Immunology – Market size and forecast 2023-2028 ($ million)
o Exhibit 44: Chart on Immunology – Year-over-year growth 2023-2028 (%)
o Exhibit 45: Data Table on Immunology – Year-over-year growth 2023-2028 (%)
o 6.6 Market opportunity by Product
o Exhibit 46: Market opportunity by Product ($ million)
o Exhibit 47: Data Table on Market opportunity by Product ($ million)
• 7 Market Segmentation by Type
o 7.1 Market segments
o Exhibit 48: Chart on Type – Market share 2023-2028 (%)
o Exhibit 49: Data Table on Type – Market share 2023-2028 (%)
o 7.2 Comparison by Type
o Exhibit 50: Chart on Comparison by Type
o Exhibit 51: Data Table on Comparison by Type
o 7.3 First generation anti-CD20 monoclonal antibody – Market size and forecast 2023-2028
o Exhibit 52: Chart on First generation anti-CD20 monoclonal antibody – Market size and forecast 2023-2028 ($ million)
o Exhibit 53: Data Table on First generation anti-CD20 monoclonal antibody – Market size and forecast 2023-2028 ($ million)
o Exhibit 54: Chart on First generation anti-CD20 monoclonal antibody – Year-over-year growth 2023-2028 (%)
o Exhibit 55: Data Table on First generation anti-CD20 monoclonal antibody – Year-over-year growth 2023-2028 (%)
o 7.4 Second generation anti-CD20 monoclonal antibody – Market size and forecast 2023-2028
o Exhibit 56: Chart on Second generation anti-CD20 monoclonal antibody – Market size and forecast 2023-2028 ($ million)
o Exhibit 57: Data Table on Second generation anti-CD20 monoclonal antibody – Market size and forecast 2023-2028 ($ million)
o Exhibit 58: Chart on Second generation anti-CD20 monoclonal antibody – Year-over-year growth 2023-2028 (%)
o Exhibit 59: Data Table on Second generation anti-CD20 monoclonal antibody – Year-over-year growth 2023-2028 (%)
o 7.5 Third generation anti-CD20 monoclonal antibody – Market size and forecast 2023-2028
o Exhibit 60: Chart on Third generation anti-CD20 monoclonal antibody – Market size and forecast 2023-2028 ($ million)
o Exhibit 61: Data Table on Third generation anti-CD20 monoclonal antibody – Market size and forecast 2023-2028 ($ million)
o Exhibit 62: Chart on Third generation anti-CD20 monoclonal antibody – Year-over-year growth 2023-2028 (%)
o Exhibit 63: Data Table on Third generation anti-CD20 monoclonal antibody – Year-over-year growth 2023-2028 (%)
o 7.6 Market opportunity by Type
o Exhibit 64: Market opportunity by Type ($ million)
o Exhibit 65: Data Table on Market opportunity by Type ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 67: Chart on Market share by geography 2023-2028 (%)
o Exhibit 68: Data Table on Market share by geography 2023-2028 (%)
o 9.2 Geographic comparison
o Exhibit 69: Chart on Geographic comparison
o Exhibit 70: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2023-2028
o Exhibit 71: Chart on North America – Market size and forecast 2023-2028 ($ million)
o Exhibit 72: Data Table on North America – Market size and forecast 2023-2028 ($ million)
o Exhibit 73: Chart on North America – Year-over-year growth 2023-2028 (%)
o Exhibit 74: Data Table on North America – Year-over-year growth 2023-2028 (%)
o 9.4 Europe – Market size and forecast 2023-2028
o Exhibit 75: Chart on Europe – Market size and forecast 2023-2028 ($ million)
o Exhibit 76: Data Table on Europe – Market size and forecast 2023-2028 ($ million)
o Exhibit 77: Chart on Europe – Year-over-year growth 2023-2028 (%)
o Exhibit 78: Data Table on Europe – Year-over-year growth 2023-2028 (%)
o 9.5 Asia – Market size and forecast 2023-2028
o Exhibit 79: Chart on Asia – Market size and forecast 2023-2028 ($ million)
o Exhibit 80: Data Table on Asia – Market size and forecast 2023-2028 ($ million)
o Exhibit 81: Chart on Asia – Year-over-year growth 2023-2028 (%)
o Exhibit 82: Data Table on Asia – Year-over-year growth 2023-2028 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2023-2028
o Exhibit 83: Chart on Rest of World (ROW) – Market size and forecast 2023-2028 ($ million)
o Exhibit 84: Data Table on Rest of World (ROW) – Market size and forecast 2023-2028 ($ million)
o Exhibit 85: Chart on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
o Exhibit 86: Data Table on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
o 9.7 US – Market size and forecast 2023-2028
o Exhibit 87: Chart on US – Market size and forecast 2023-2028 ($ million)
o Exhibit 88: Data Table on US – Market size and forecast 2023-2028 ($ million)
o Exhibit 89: Chart on US – Year-over-year growth 2023-2028 (%)
o Exhibit 90: Data Table on US – Year-over-year growth 2023-2028 (%)
o 9.8 Canada – Market size and forecast 2023-2028
o Exhibit 91: Chart on Canada – Market size and forecast 2023-2028 ($ million)
o Exhibit 92: Data Table on Canada – Market size and forecast 2023-2028 ($ million)
o Exhibit 93: Chart on Canada – Year-over-year growth 2023-2028 (%)
o Exhibit 94: Data Table on Canada – Year-over-year growth 2023-2028 (%)
o 9.9 Germany – Market size and forecast 2023-2028
o Exhibit 95: Chart on Germany – Market size and forecast 2023-2028 ($ million)
o Exhibit 96: Data Table on Germany – Market size and forecast 2023-2028 ($ million)
o Exhibit 97: Chart on Germany – Year-over-year growth 2023-2028 (%)
o Exhibit 98: Data Table on Germany – Year-over-year growth 2023-2028 (%)
o 9.10 UK – Market size and forecast 2023-2028
o Exhibit 99: Chart on UK – Market size and forecast 2023-2028 ($ million)
o Exhibit 100: Data Table on UK – Market size and forecast 2023-2028 ($ million)
o Exhibit 101: Chart on UK – Year-over-year growth 2023-2028 (%)
o Exhibit 102: Data Table on UK – Year-over-year growth 2023-2028 (%)
o 9.11 China – Market size and forecast 2023-2028
o Exhibit 103: Chart on China – Market size and forecast 2023-2028 ($ million)
o Exhibit 104: Data Table on China – Market size and forecast 2023-2028 ($ million)
o Exhibit 105: Chart on China – Year-over-year growth 2023-2028 (%)
o Exhibit 106: Data Table on China – Year-over-year growth 2023-2028 (%)
o 9.12 Market opportunity by geography
o Exhibit 107: Market opportunity by geography ($ million)
o Exhibit 108: Data Tables on Market opportunity by geography ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 109: Impact of drivers and challenges in 2023 and 2028
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 111: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 112: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 113: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 114: Matrix on vendor position and classification
o 12.3 Acrotech Biopharma Inc.
o Exhibit 115: Acrotech Biopharma Inc. – Overview
o Exhibit 116: Acrotech Biopharma Inc. – Product / Service
o Exhibit 117: Acrotech Biopharma Inc. – Key offerings
o 12.4 Amgen Inc.
o Exhibit 118: Amgen Inc. – Overview
o Exhibit 119: Amgen Inc. – Product / Service
o Exhibit 120: Amgen Inc. – Key offerings
o 12.5 AstraZeneca Plc
o Exhibit 121: AstraZeneca Plc – Overview
o Exhibit 122: AstraZeneca Plc – Product / Service
o Exhibit 123: AstraZeneca Plc – Key news
o Exhibit 124: AstraZeneca Plc – Key offerings
o 12.6 Celltrion Healthcare Co. Ltd.
o Exhibit 125: Celltrion Healthcare Co. Ltd. – Overview
o Exhibit 126: Celltrion Healthcare Co. Ltd. – Product / Service
o Exhibit 127: Celltrion Healthcare Co. Ltd. – Key offerings
o 12.7 F. Hoffmann La Roche Ltd.
o Exhibit 128: F. Hoffmann La Roche Ltd. – Overview
o Exhibit 129: F. Hoffmann La Roche Ltd. – Business segments
o Exhibit 130: F. Hoffmann La Roche Ltd. – Key news
o Exhibit 131: F. Hoffmann La Roche Ltd. – Key offerings
o Exhibit 132: F. Hoffmann La Roche Ltd. – Segment focus
o 12.8 Fosun International Ltd.
o Exhibit 133: Fosun International Ltd. – Overview
o Exhibit 134: Fosun International Ltd. – Product / Service
o Exhibit 135: Fosun International Ltd. – Key offerings
o 12.9 Genmab AS
o Exhibit 136: Genmab AS – Overview
o Exhibit 137: Genmab AS – Key offerings
o 12.10 IGM Biosciences Inc.
o Exhibit 138: IGM Biosciences Inc. – Overview
o Exhibit 139: IGM Biosciences Inc. – Product / Service
o Exhibit 140: IGM Biosciences Inc. – Key offerings
o 12.11 JSC BIOCAD
o Exhibit 141: JSC BIOCAD – Overview
o Exhibit 142: JSC BIOCAD – Product / Service
o Exhibit 143: JSC BIOCAD – Key offerings
o 12.12 LFB SA
o Exhibit 144: LFB SA – Overview
o Exhibit 145: LFB SA – Product / Service
o Exhibit 146: LFB SA – Key offerings
o 12.13 Novartis AG
o Exhibit 147: Novartis AG – Overview
o Exhibit 148: Novartis AG – Business segments
o Exhibit 149: Novartis AG – Key offerings
o Exhibit 150: Novartis AG – Segment focus
o 12.14 Pfizer Inc.
o Exhibit 151: Pfizer Inc. – Overview
o Exhibit 152: Pfizer Inc. – Product / Service
o Exhibit 153: Pfizer Inc. – Key news
o Exhibit 154: Pfizer Inc. – Key offerings
o 12.15 Regeneron Pharmaceuticals Inc.
o Exhibit 155: Regeneron Pharmaceuticals Inc. – Overview
o Exhibit 156: Regeneron Pharmaceuticals Inc. – Product / Service
o Exhibit 157: Regeneron Pharmaceuticals Inc. – Key offerings
o 12.16 Spectrum Pharmaceuticals Inc.
o Exhibit 158: Spectrum Pharmaceuticals Inc. – Overview
o Exhibit 159: Spectrum Pharmaceuticals Inc. – Product / Service
o Exhibit 160: Spectrum Pharmaceuticals Inc. – Key offerings
o 12.17 TG Therapeutics Inc.
o Exhibit 161: TG Therapeutics Inc. – Overview
o Exhibit 162: TG Therapeutics Inc. – Product / Service
o Exhibit 163: TG Therapeutics Inc. – Key offerings
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 164: Inclusions checklist
o Exhibit 165: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 166: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 167: Research methodology
o Exhibit 168: Validation techniques employed for market sizing
o Exhibit 169: Information sources
o 13.5 List of abbreviations
o Exhibit 170: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market by Geography
Exhibits5: Executive Summary – Chart on Market Segmentation by Product
Exhibits6: Executive Summary – Chart on Market Segmentation by Type
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2023-2028 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2023-2028 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits18: Historic Market Size – Data Table on global anti-cd20 monoclonal antibodies (mabs) market 2018 – 2022 ($ million)
Exhibits19: Historic Market Size – Product Segment 2018 – 2022 ($ million)
Exhibits20: Historic Market Size – Type Segment 2018 – 2022 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2018 – 2022 ($ million)
Exhibits22: Historic Market Size – Country Segment 2018 – 2022 ($ million)
Exhibits23: Five forces analysis – Comparison between 2023 and 2028
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
Exhibits26: Threat of new entrants – Impact of key factors in 2023 and 2028
Exhibits27: Threat of substitutes – Impact of key factors in 2023 and 2028
Exhibits28: Threat of rivalry – Impact of key factors in 2023 and 2028
Exhibits29: Chart on Market condition – Five forces 2023 and 2028
Exhibits30: Chart on Product – Market share 2023-2028 (%)
Exhibits31: Data Table on Product – Market share 2023-2028 (%)
Exhibits32: Chart on Comparison by Product
Exhibits33: Data Table on Comparison by Product
Exhibits34: Chart on Oncology – Market size and forecast 2023-2028 ($ million)
Exhibits35: Data Table on Oncology – Market size and forecast 2023-2028 ($ million)
Exhibits36: Chart on Oncology – Year-over-year growth 2023-2028 (%)
Exhibits37: Data Table on Oncology – Year-over-year growth 2023-2028 (%)
Exhibits38: Chart on Neurology – Market size and forecast 2023-2028 ($ million)
Exhibits39: Data Table on Neurology – Market size and forecast 2023-2028 ($ million)
Exhibits40: Chart on Neurology – Year-over-year growth 2023-2028 (%)
Exhibits41: Data Table on Neurology – Year-over-year growth 2023-2028 (%)
Exhibits42: Chart on Immunology – Market size and forecast 2023-2028 ($ million)
Exhibits43: Data Table on Immunology – Market size and forecast 2023-2028 ($ million)
Exhibits44: Chart on Immunology – Year-over-year growth 2023-2028 (%)
Exhibits45: Data Table on Immunology – Year-over-year growth 2023-2028 (%)
Exhibits46: Market opportunity by Product ($ million)
Exhibits47: Data Table on Market opportunity by Product ($ million)
Exhibits48: Chart on Type – Market share 2023-2028 (%)
Exhibits49: Data Table on Type – Market share 2023-2028 (%)
Exhibits50: Chart on Comparison by Type
Exhibits51: Data Table on Comparison by Type
Exhibits52: Chart on First generation anti-CD20 monoclonal antibody – Market size and forecast 2023-2028 ($ million)
Exhibits53: Data Table on First generation anti-CD20 monoclonal antibody – Market size and forecast 2023-2028 ($ million)
Exhibits54: Chart on First generation anti-CD20 monoclonal antibody – Year-over-year growth 2023-2028 (%)
Exhibits55: Data Table on First generation anti-CD20 monoclonal antibody – Year-over-year growth 2023-2028 (%)
Exhibits56: Chart on Second generation anti-CD20 monoclonal antibody – Market size and forecast 2023-2028 ($ million)
Exhibits57: Data Table on Second generation anti-CD20 monoclonal antibody – Market size and forecast 2023-2028 ($ million)
Exhibits58: Chart on Second generation anti-CD20 monoclonal antibody – Year-over-year growth 2023-2028 (%)
Exhibits59: Data Table on Second generation anti-CD20 monoclonal antibody – Year-over-year growth 2023-2028 (%)
Exhibits60: Chart on Third generation anti-CD20 monoclonal antibody – Market size and forecast 2023-2028 ($ million)
Exhibits61: Data Table on Third generation anti-CD20 monoclonal antibody – Market size and forecast 2023-2028 ($ million)
Exhibits62: Chart on Third generation anti-CD20 monoclonal antibody – Year-over-year growth 2023-2028 (%)
Exhibits63: Data Table on Third generation anti-CD20 monoclonal antibody – Year-over-year growth 2023-2028 (%)
Exhibits64: Market opportunity by Type ($ million)
Exhibits65: Data Table on Market opportunity by Type ($ million)
Exhibits66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits67: Chart on Market share by geography 2023-2028 (%)
Exhibits68: Data Table on Market share by geography 2023-2028 (%)
Exhibits69: Chart on Geographic comparison
Exhibits70: Data Table on Geographic comparison
Exhibits71: Chart on North America – Market size and forecast 2023-2028 ($ million)
Exhibits72: Data Table on North America – Market size and forecast 2023-2028 ($ million)
Exhibits73: Chart on North America – Year-over-year growth 2023-2028 (%)
Exhibits74: Data Table on North America – Year-over-year growth 2023-2028 (%)
Exhibits75: Chart on Europe – Market size and forecast 2023-2028 ($ million)
Exhibits76: Data Table on Europe – Market size and forecast 2023-2028 ($ million)
Exhibits77: Chart on Europe – Year-over-year growth 2023-2028 (%)
Exhibits78: Data Table on Europe – Year-over-year growth 2023-2028 (%)
Exhibits79: Chart on Asia – Market size and forecast 2023-2028 ($ million)
Exhibits80: Data Table on Asia – Market size and forecast 2023-2028 ($ million)
Exhibits81: Chart on Asia – Year-over-year growth 2023-2028 (%)
Exhibits82: Data Table on Asia – Year-over-year growth 2023-2028 (%)
Exhibits83: Chart on Rest of World (ROW) – Market size and forecast 2023-2028 ($ million)
Exhibits84: Data Table on Rest of World (ROW) – Market size and forecast 2023-2028 ($ million)
Exhibits85: Chart on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
Exhibits86: Data Table on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
Exhibits87: Chart on US – Market size and forecast 2023-2028 ($ million)
Exhibits88: Data Table on US – Market size and forecast 2023-2028 ($ million)
Exhibits89: Chart on US – Year-over-year growth 2023-2028 (%)
Exhibits90: Data Table on US – Year-over-year growth 2023-2028 (%)
Exhibits91: Chart on Canada – Market size and forecast 2023-2028 ($ million)
Exhibits92: Data Table on Canada – Market size and forecast 2023-2028 ($ million)
Exhibits93: Chart on Canada – Year-over-year growth 2023-2028 (%)
Exhibits94: Data Table on Canada – Year-over-year growth 2023-2028 (%)
Exhibits95: Chart on Germany – Market size and forecast 2023-2028 ($ million)
Exhibits96: Data Table on Germany – Market size and forecast 2023-2028 ($ million)
Exhibits97: Chart on Germany – Year-over-year growth 2023-2028 (%)
Exhibits98: Data Table on Germany – Year-over-year growth 2023-2028 (%)
Exhibits99: Chart on UK – Market size and forecast 2023-2028 ($ million)
Exhibits100: Data Table on UK – Market size and forecast 2023-2028 ($ million)
Exhibits101: Chart on UK – Year-over-year growth 2023-2028 (%)
Exhibits102: Data Table on UK – Year-over-year growth 2023-2028 (%)
Exhibits103: Chart on China – Market size and forecast 2023-2028 ($ million)
Exhibits104: Data Table on China – Market size and forecast 2023-2028 ($ million)
Exhibits105: Chart on China – Year-over-year growth 2023-2028 (%)
Exhibits106: Data Table on China – Year-over-year growth 2023-2028 (%)
Exhibits107: Market opportunity by geography ($ million)
Exhibits108: Data Tables on Market opportunity by geography ($ million)
Exhibits109: Impact of drivers and challenges in 2023 and 2028
Exhibits110: Overview on Criticality of inputs and Factors of differentiation
Exhibits111: Overview on factors of disruption
Exhibits112: Impact of key risks on business
Exhibits113: Vendors covered
Exhibits114: Matrix on vendor position and classification
Exhibits115: Acrotech Biopharma Inc. – Overview
Exhibits116: Acrotech Biopharma Inc. – Product / Service
Exhibits117: Acrotech Biopharma Inc. – Key offerings
Exhibits118: Amgen Inc. – Overview
Exhibits119: Amgen Inc. – Product / Service
Exhibits120: Amgen Inc. – Key offerings
Exhibits121: AstraZeneca Plc – Overview
Exhibits122: AstraZeneca Plc – Product / Service
Exhibits123: AstraZeneca Plc – Key news
Exhibits124: AstraZeneca Plc – Key offerings
Exhibits125: Celltrion Healthcare Co. Ltd. – Overview
Exhibits126: Celltrion Healthcare Co. Ltd. – Product / Service
Exhibits127: Celltrion Healthcare Co. Ltd. – Key offerings
Exhibits128: F. Hoffmann La Roche Ltd. – Overview
Exhibits129: F. Hoffmann La Roche Ltd. – Business segments
Exhibits130: F. Hoffmann La Roche Ltd. – Key news
Exhibits131: F. Hoffmann La Roche Ltd. – Key offerings
Exhibits132: F. Hoffmann La Roche Ltd. – Segment focus
Exhibits133: Fosun International Ltd. – Overview
Exhibits134: Fosun International Ltd. – Product / Service
Exhibits135: Fosun International Ltd. – Key offerings
Exhibits136: Genmab AS – Overview
Exhibits137: Genmab AS – Key offerings
Exhibits138: IGM Biosciences Inc. – Overview
Exhibits139: IGM Biosciences Inc. – Product / Service
Exhibits140: IGM Biosciences Inc. – Key offerings
Exhibits141: JSC BIOCAD – Overview
Exhibits142: JSC BIOCAD – Product / Service
Exhibits143: JSC BIOCAD – Key offerings
Exhibits144: LFB SA – Overview
Exhibits145: LFB SA – Product / Service
Exhibits146: LFB SA – Key offerings
Exhibits147: Novartis AG – Overview
Exhibits148: Novartis AG – Business segments
Exhibits149: Novartis AG – Key offerings
Exhibits150: Novartis AG – Segment focus
Exhibits151: Pfizer Inc. – Overview
Exhibits152: Pfizer Inc. – Product / Service
Exhibits153: Pfizer Inc. – Key news
Exhibits154: Pfizer Inc. – Key offerings
Exhibits155: Regeneron Pharmaceuticals Inc. – Overview
Exhibits156: Regeneron Pharmaceuticals Inc. – Product / Service
Exhibits157: Regeneron Pharmaceuticals Inc. – Key offerings
Exhibits158: Spectrum Pharmaceuticals Inc. – Overview
Exhibits159: Spectrum Pharmaceuticals Inc. – Product / Service
Exhibits160: Spectrum Pharmaceuticals Inc. – Key offerings
Exhibits161: TG Therapeutics Inc. – Overview
Exhibits162: TG Therapeutics Inc. – Product / Service
Exhibits163: TG Therapeutics Inc. – Key offerings
Exhibits164: Inclusions checklist
Exhibits165: Exclusions checklist
Exhibits166: Currency conversion rates for US$
Exhibits167: Research methodology
Exhibits168: Validation techniques employed for market sizing
Exhibits169: Information sources
Exhibits170: List of abbreviations



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(IRTNTR73017-23 )"抗CD20モノクローナル抗体(mAB)の世界市場2024~2028" (英文:Global Anti-CD20 Monoclonal Antibodies (mABs) Market 2024-2028)はTechnavio社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。